Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently without UK marketing authorisation from the MHRA or EMA
Activity optimization : Exercise is crucial, but the type and timing matterespecially for hormone balance
Though most GLP-1RAs are approved only for T2D, semaglutide and liraglutide are also approved for weight loss likely driven by GLP-1RAs actions on satiety and gastric emptying
Insurance coverage for these therapies is often limited or inconsistent, which can restrict individualized care
Adler said as many as 10% of the ADHD patients he treats are currently taking GLP-1s
This article explains what retatrutide is, how it works, its current regulatory status, and what anyone considering involvement in a clinical trial should know about safety and side effects